China
# |
Name |
Revenue Per Share |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 107.02
|
March 31, 2024 | USD 1.59 | NA |
|
China |
|
2 |
USD 26.96
|
Dec. 31, 2023 | USD 2.63 | 1.97% |
|
China |
|
3 |
USD 19.08
|
Dec. 31, 2023 | USD 3.55 | 0.97% |
|
China |
|
4 |
USD 14.53
|
Dec. 31, 2023 | USD 1.74 | -0.17% |
|
China |
|
5 |
USD 10.07
|
Dec. 31, 2023 | USD 1.44 | 1.17% |
|
China |
|
6 |
USD 9.91
|
Dec. 31, 2023 | USD 1.60 | 0.80% |
|
China |
|
7 |
USD 9.28
|
Dec. 31, 2023 | USD 4.45 | 1.06% |
|
China |
|
8 |
USD 8.31
|
Dec. 31, 2023 | USD 3.06 | 1.51% |
|
China |
|
9 |
USD 8.11
|
Dec. 31, 2023 | USD 2.42 | 1.06% |
|
China |
|
10 |
USD 7.39
|
Dec. 31, 2023 | USD 6.68 | -1.47% |
|
China |
|
11 |
USD 7.23
|
Dec. 31, 2023 | USD 1.14 | 1.38% |
|
China |
|
12 |
USD 6.55
|
Dec. 31, 2023 | USD 0.71 | 0.89% |
|
China |
|
13 |
USD 6.54
|
Dec. 31, 2023 | USD 2.25 | 1.02% |
|
China |
|
14 |
USD 5.84
|
Dec. 31, 2023 | USD 0.67 | 1.36% |
|
China |
|
15 |
USD 5.41
|
Dec. 31, 2023 | USD 0.69 | 1.33% |
|
China |
|
16 |
USD 4.16
|
Dec. 31, 2023 | USD 2.18 | 0.03% |
|
China |
|
17 |
USD 4.08
|
Dec. 31, 2023 | USD 1.72 | 1.45% |
|
China |
|
18 |
USD 4.06
|
Dec. 31, 2023 | USD 32.04 | -0.79% |
|
China |
|
19 |
USD 3.96
|
Dec. 31, 2023 | USD 2.59 | -2.23% |
|
China |
|
20 |
USD 3.88
|
Dec. 31, 2023 | USD 5.83 | 0.29% |
|
China |
|
21 |
USD 3.66
|
Dec. 31, 2023 | USD 1.46 | -0.75% |
|
China |
|
22 |
USD 3.25
|
Dec. 31, 2023 | USD 4.80 | 1.93% |
|
China |
|
23 |
USD 3.16
|
Dec. 31, 2023 | USD 3.16 | 0.74% |
|
China |
|
24 |
USD 3.11
|
Dec. 31, 2023 | USD 3.32 | -1.00% |
|
China |
|
25 |
USD 3.08
|
Dec. 31, 2023 | USD 7.99 | 0.90% |
|
China |
|
26 |
USD 3.05
|
Dec. 31, 2023 | USD 1.95 | 1.92% |
|
China |
|
27 |
USD 3.05
|
Dec. 31, 2023 | USD 1.44 | -2.25% |
|
China |
|
28 |
USD 3.04
|
Dec. 31, 2023 | USD 10.27 | -0.41% |
|
China |
|
29 |
USD 3.01
|
Dec. 31, 2023 | USD 1.46 | -0.02% |
|
China |
|
30 |
USD 2.92
|
Dec. 31, 2023 | USD 1.31 | 1.38% |
|
China |
|
31 |
USD 2.76
|
Dec. 31, 2023 | USD 2.63 | -0.26% |
|
China |
|
32 |
USD 2.72
|
Dec. 31, 2023 | USD 6.10 | 0.02% |
|
China |
|
33 |
USD 2.58
|
Dec. 31, 2023 | USD 3.37 | -1.70% |
|
China |
|
34 |
USD 2.52
|
Dec. 31, 2023 | USD 0.99 | -0.51% |
|
China |
|
35 |
USD 2.41
|
Dec. 31, 2023 | USD 52.19 | 2.06% |
|
China |
|
36 |
USD 2.37
|
Dec. 31, 2023 | USD 2.21 | -0.22% |
|
China |
|
37 |
USD 2.22
|
Dec. 31, 2023 | USD 2.25 | 1.02% |
|
China |
|
38 |
USD 2.17
|
Dec. 31, 2023 | USD 1.72 | 0.73% |
|
China |
|
39 |
USD 2.14
|
Dec. 31, 2023 | USD 3.00 | -0.82% |
|
China |
|
40 |
USD 2.08
|
Dec. 31, 2023 | USD 3.88 | -0.13% |
|
China |
|
41 |
USD 1.95
|
Dec. 31, 2023 | USD 0.33 | 1.19% |
|
China |
|
42 |
USD 1.92
|
Dec. 31, 2023 | USD 7.19 | 0.25% |
|
China |
|
43 |
USD 1.88
|
Dec. 31, 2023 | USD 3.38 | -0.40% |
|
China |
|
44 |
USD 1.83
|
Dec. 31, 2023 | USD 5.10 | 0.50% |
|
China |
|
45 |
USD 1.81
|
Dec. 31, 2023 | USD 9.61 | -0.14% |
|
China |
|
46 |
USD 1.70
|
Dec. 31, 2023 | USD 1.05 | 0.96% |
|
China |
|
47 |
USD 1.69
|
Dec. 31, 2023 | USD 2.01 | -0.43% |
|
China |
|
48 |
USD 1.66
|
Dec. 31, 2023 | USD 7.07 | -1.23% |
|
China |
|
49 |
USD 1.66
|
Dec. 31, 2023 | USD 2.24 | 9.10% |
|
China |
|
50 |
USD 1.65
|
Dec. 31, 2023 | USD 0.73 | 0.16% |
|
China |
The Healthcare company in China with the highest Revenue Per Share is China Jo-Jo Drugstores, Inc. (NasdaqCM: CJJD) at USD 107.02.
The Healthcare company in China with the lowest Revenue Per Share is Shanghai Bio-heart Biological Technology Co., Ltd. (HKSE: 2185.HK) at USD 0.00.
The top 10 Healthcare companies in China by Revenue Per Share are China Jo-Jo Drugstores, Inc., Sinopharm Group Co. Ltd., China National Accord Medicines Corporation Ltd., Cachet Pharmaceutical Co., Ltd., Zhejiang Int'l Group Co.,Ltd., Shanghai Pharmaceuticals Holding Co., Ltd, China National Medicines Corporation Ltd., Yunnan Jianzhijia Health-Chain Co., Ltd., Guangxi LiuYao Group Co., Ltd and Burning Rock Biotech Limited.
The bottom 10 Healthcare companies in China by Revenue Per Share are Shanghai Bio-heart Biological Technology Co., Ltd., Genor Biopharma Holdings Limited, Connect Biopharma Holdings Limited, HighTide Therapeutics Inc, ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Abbisko Cayman Limited, Ascletis Pharma Inc., Hua Medicine (Shanghai) Ltd., Jacobio Pharmaceuticals Group Co., Ltd. and Lepu Biopharma Co., Ltd..